stockrow
Wednesday 4 November 2026
Export ASMB’s income statement to Excel — free account
Assembly Biosciences, Inc.
ASMB Healthcare Biotechnology
Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024.
- Revenue
- +38.9%
- EPS
- +85.0%
- Free cash flow
- +7.58%
Quarter to June 2026, against a year earlier
19.80
0.12
−0.60%
Follow ASMB
Alert me
Assembly Biosciences, Inc. (ASMB) P/E ratio
Assembly Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BLSM BlossomHill Therapeutics, Inc. compare | n/m |
| ASMB Assembly Biosciences, Inc. | n/m |
| AVTX Avalo Therapeutics, Inc. compare | n/m |
| EDIT Editas Medicine, Inc. compare | n/m |
| ALT Altimmune, Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| ZURA Zura Bio Limited compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | n/m |
| CCCC C4 Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.6× |
| Market median | 18.3× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)